Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Fredun Pharmaceuticals Ltd (FREDUN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539730 NSE: FREDUN Pharmaceuticals & Drugs | Small Cap | Fredun Pharma Share Price
₹1,396 48.45 (3.60%)
As on 22-Sep'26 12:11
Fredun Pharmaceuticals Ltd (FREDUN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539730 NSE: FREDUN Pharmaceuticals & Drugs | Small Cap | Fredun Pharma Share Price
₹1,396 48.45 (3.60%)
As on 22-Sep'26 12:11
Key Metrics
Valuation Multiples
Market Cap
₹2,265 Cr.
Current Price
₹1,396
52-Week Low / High
₹391 / 1,600
TTM EPS
₹26.1
TTM Sales
₹742 Cr.
Book Value per Share
₹174.7
P/E Ratio
51.69
Higher than its 5-year historical median
Industry PE
55.1
Price to Book (P/B)
7.71
Higher than its 5-year historical median
Price to Sales (P/S)
3.05
Higher than its 5-year historical median
EV/EBITDA
21.97
Higher than its 5-year historical median
Dividend Yield
0.02%
Profitability Efficiency
Return on Equity (ROE)
16.09%
Return on Capital Employed (ROCE)
21.34%
Return on Assets (ROA)
5.78%
Outperforms industry median
Operating Profit Margin
14.3%
Net Profit Margin
5.13%
Gross Profit Margin
8.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
40.03%
Operating Profit Growth (1 Year)
-
73.29%
Net Profit Growth (1 Year)
-
65.25%
Asset Quality
Promoter Holding
44.57%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹277 Cr.
Equity
₹16.8 Cr.
Face Value
₹10
All Time Low / High
₹4.17 / 1600.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Fredun Pharmaceuticals Ltd a good quality company?
Fredun Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Fredun Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Fredun Pharmaceuticals Ltd vs industry peers?
Fredun Pharmaceuticals Ltd revenue CAGR is %, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Fredun Pharmaceuticals Ltd?
Promoters hold 44.57% of the Fredun Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Fredun Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 66.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Fredun Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.2% | 15.9% | 20.6% | 10.4% | 9.5% | 13.2% | 17.6% | 17.1% | 18.9% | 21.5% | - |
| Value Creation Index ⓘ | 0.3 | 0.1 | 0.5 | -0.3 | -0.3 | -0.1 | 0.3 | 0.2 | 0.4 | 0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 56.7 | 59.6 | 97 | 113 | 134 | 224 | 275 | 348 | 454 | 635 | 742 |
| Sales YoY Gr. | - | 5% | 62.9% | 16.2% | 18.7% | 67.7% | 22.4% | 26.8% | 30.4% | 40% | - |
| Adj EPS ⓘ | 1.2 | 1.6 | 3.8 | 1.5 | 1.7 | 4.1 | 7.2 | 10.7 | 14.7 | 19 | 26.4 |
| YoY Gr. | - | 38.5% | 137% | -62.2% | 13.8% | 150.9% | 73.7% | 49.2% | 36.6% | 29.3% | - |
| BVPS (₹) ⓘ | 6.7 | 21.6 | 32.6 | 34.5 | 36 | 51 | 64.8 | 85.1 | 99.8 | 161.3 | 175.1 |
| Adj Net Profit ⓘ | 0.8 | 1.7 | 4.6 | 1.7 | 2 | 5.5 | 9.8 | 15.1 | 20.8 | 31.1 | 44 |
| Cash Flow from Ops. ⓘ | 4 | 17.3 | 0.8 | -10.6 | 0.2 | -2.4 | -14.4 | -0.4 | -21 | 16.4 | - |
| Debt/CF from Ops. ⓘ | 4.6 | 0.6 | 23.1 | -3.3 | 233.3 | -22.2 | -6 | -240.5 | -7.9 | 13.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 30.8% | 36.5% | 32.3% | 40% | ||||
| Adj EPS ⓘ | 36.3% | 62.9% | 38.1% | 29.3% | ||||
| BVPSⓘ | 42.4% | 35% | 35.6% | 61.6% | ||||
| Share Price | 66.9% | 49.5% | 68.5% | 244.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.8 | 11.3 | 15 | 4.3 | 4.7 | 9.9 | 11.9 | 13.9 | 15.8 | 14.8 | 15.7 |
| Op. Profit Mgn % ⓘ | 6 | 9.6 | 10.5 | 7.4 | 7 | 6.2 | 10.1 | 10.9 | 11.8 | 14.4 | 14.9 |
| Net Profit Mgn % ⓘ | 1.5 | 2.8 | 4.7 | 1.5 | 1.5 | 2.5 | 3.6 | 4.3 | 4.6 | 4.9 | 6 |
| Debt to Equity ⓘ | 2.5 | 0.5 | 0.5 | 0.8 | 0.9 | 0.8 | 1 | 0.9 | 1.2 | 0.8 | - |
| Working Cap Days ⓘ | 200 | 261 | 230 | 290 | 324 | 230 | 244 | 248 | 278 | 255 | 114 |
| Cash Conv. Cycle ⓘ | 12 | -31 | 15 | 98 | 111 | 100 | 135 | 149 | 166 | 143 | 40 |
Valuation of Fredun Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 454 | 635 |
| Operating Expenses ⓘ + | 401 | 545 |
| Operating Profit ⓘ | 52 | 91 |
| Operating Profit Margin (%) | 11.6% | 14.3% |
| Other Income ⓘ + | 2 | 4 |
| Interest ⓘ | 22 | 39 |
| Depreciation ⓘ | 5 | 8 |
| Profit Before Tax ⓘ | 27 | 47 |
| Tax ⓘ | 8 | 14 |
| Profit After Tax | 20 | 33 |
| PAT Margin (%) | 4.4% | 5.1% |
| Adjusted EPS (₹) | 13.9 | 19.9 |
| Dividend Payout Ratio (%) | 1.70% | 1.20% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 141 | 264 | |||||||||
| Debt + | 160 | 203 | |||||||||
| Minority Interest | 0 | -0 | |||||||||
| Trade Payables | 145 | 88 | |||||||||
| Others Liabilities ⓘ | 41 | 88 | |||||||||
| Total Liabilities ⓘ | 487 | 642 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 53 | 118 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 2 | 2 | |||||||||
| Inventories | 240 | 270 | |||||||||
| Trade Receivables | 177 | 93 | |||||||||
| Cash Equivalents | 5 | 65 | |||||||||
| Others Assets ⓘ | 11 | 94 | |||||||||
| Total Assets ⓘ | 487 | 642 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -17 | 12 |
| Cash Flow From Investing Activity ⓘ + | -6 | -74 |
| Cash Flow From Financing Activity ⓘ + | 27 | 121 |
| Net Cash Flow ⓘ | 4 | 60 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 13.96 | 16.09 | ||||||||
| ROCE (%) | 16.16 | 21.34 | ||||||||
| Asset Turnover Ratio | 0.93 | 1.13 | ||||||||
| PAT to CFO Conversion(x) | -0.85 | 0.36 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 142.50 | 77.50 | ||||||||
| Inventory Days | 192.90 | 146.40 | ||||||||
| Payable Days | 160.10 | 93.40 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Fredun Pharmaceuticals Ltd FAQs
The current trading price of Fredun Pharma on 22-Sep-2026 12:11 is ₹1,396.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Fredun Pharma stood at ₹2,265.1 Cr
The latest P/E ratio of Fredun Pharma as of 21-Sep-2026 is 50.97.
The latest P/B ratio of Fredun Pharma as of 21-Sep-2026 is 7.70.
The 52-week high of Fredun Pharma is ₹1,600 and the 52-week low is ₹390.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fredun Pharma is ₹742 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Fredun Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Fredun Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Fredun Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Fredun Pharmaceuticals Ltd
No data to display
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
